The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study.
 
Juan W. Valle
No Relationships to Disclose
 
Li-Yuan Bai
No Relationships to Disclose
 
Rashida Orlova
No Relationships to Disclose
 
Eric Van Cutsem
No Relationships to Disclose
 
Jorge Adeva Alfonso
No Relationships to Disclose
 
Li-Tzong Chen
No Relationships to Disclose
 
Radka Obermannova
No Relationships to Disclose
 
Thomas Jens Ettrich
No Relationships to Disclose
 
Jen-Shi Chen
No Relationships to Disclose
 
Harpreet Singh Wasan
No Relationships to Disclose
 
Crystal S. Denlinger
No Relationships to Disclose
 
Arndt Vogel
No Relationships to Disclose
 
Aiwu Ruth He
No Relationships to Disclose
 
Nathalie Bousmans
No Relationships to Disclose
 
Allicia C Girvan
No Relationships to Disclose
 
Wei Zhang
No Relationships to Disclose
 
Richard A. Walgren
No Relationships to Disclose
 
Roberto Carlesi
No Relationships to Disclose
 
Do-Youn Oh
No Relationships to Disclose